Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials

Status Not yet recruiting

Clinical Trial Summary

The study seeks to delve into the firsthand experiences of patients diagnosed with rhabdomyosarcoma who partake in a separate clinical trial featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals. The data collected from this study will help improve future outcomes for all rhabdomyosarcoma patients as well as those in under-represented demographic groups.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Rhabdomyosarcoma

Clinical Trial Details

NCT number	NCT06029465
Study type	Observational
Source	Power Life Sciences Inc.
Contact	Michael B Gill
Phone	(415) 900-4227
Email	bask@withpower.com
Status	Not yet recruiting
Phase
Start date	October 2024
Completion date	October 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04388839` - Evolutionary Therapy for Rhabdomyosarcoma	Phase 2
Withdrawn	`NCT04906876` - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas	Phase 2
Completed	`NCT01674101` - Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy	N/A
Completed	`NCT00520936` - A Study of Pemetrexed in Children With Recurrent Cancer	Phase 2
Completed	`NCT03655587` - Impact of an Orthotic Intervention in Children With Peripheral Neuropathy	N/A
Recruiting	`NCT06094101` - Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)	Phase 1/Phase 2
Recruiting	`NCT04625907` - FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma	Phase 1/Phase 2
Active, not recruiting	`NCT04095221` - A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma	Phase 1/Phase 2
Completed	`NCT01661400` - Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors	Phase 1
Recruiting	`NCT04337177` - Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors	Phase 1
Active, not recruiting	`NCT02945800` - Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma	Phase 2
Terminated	`NCT02536183` - A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors	Phase 1
Recruiting	`NCT00592592` - Proton RT for the Treatment of Pediatric Rhabdomyosarcoma	Phase 2
Completed	`NCT00187174` - Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors	Phase 1
Completed	`NCT01505569` - Auto Transplant for High Risk or Relapsed Solid or CNS Tumors	N/A
Active, not recruiting	`NCT03220035` - Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Completed	`NCT05093322` - A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors	Phase 1/Phase 2
Completed	`NCT04956198` - Drug Sensitivity and Mutation Profiling
Recruiting	`NCT04791228` - A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors	Phase 2
Active, not recruiting	`NCT03709680` - Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors	Phase 1/Phase 2